Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

Immunogenicity of Influenza Vaccinations

A legfontosabb adatok

Ki végzi
Duke University
Hol
Atlanta, Cleveland, Phoenix, Pittsburgh, St Louis és Tempe (Egyesült Államok)Mind a 7 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
606 fő vett részt
Kezdés
2024. szept. 9.
Befejezés
2025. jún. 4.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Flucelvax® (ccIIV3)
  • Flublok® (RIV3)
A regiszteradat frissítve
2026. július 28.

Ki vehet részt

Életkor
18 év – 64 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults aged 18-64 years that have not received the current season's influenza vaccine
  • English literate
  • Email or text message capability for weekly follow-up
  • Intention of receiving influenza vaccine based on ACIP-CDC guidelines
  • Willing to provide written/electronic informed consent
  • Intention of being available for entire study period and able to complete all relevant study procedures, including follow-up phone calls and clinic visits

Ki nem vehet részt

  • Receipt of the current season's influenza vaccine (receipt after July 1, 2024)
  • History of severe allergic reaction after a previous dose of any influenza vaccine or to an influenza vaccine component
  • Receipt of any licensed or investigational live vaccine within 6 weeks or non-live vaccine within 2 weeks prior to enrollment in this study or planning receipt of any vaccines between visits 1 and 2 of the study (approximately within 4 weeks after the receipt of study-administered vaccine)
  • History of febrile illness (> 100.0°F or 37.8°C) within the past 72 hours prior to vaccine administration
  • History of Guillain-Barré syndrome
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Any condition which, in the opinion of the investigators, may pose a health risk to the participant or interfere with the evaluation of the study objectives; Temporary Delay Criteria (Visit 1)
  • Currently pregnant, planning to become pregnant within the first three months of the study per participant self-report

Helyszínek itt: Egyesült Államok

  • Centers for Disease Control and PreventionAtlanta, Egyesült Államok
  • University Hospitals Cleveland Medical Center*Cleveland, Egyesült Államok
  • VA Northeast Ohio Healthcare System (VANEOHS)Cleveland, Egyesült Államok
  • Valleywise Health Comprehensive Health CenterPhoenix, Egyesült Államok
  • Department of Family Medicine, University of Pittsburgh School of MedicinePittsburgh, Egyesült Államok
  • Washington University IDCRUSt Louis, Egyesült Államok
  • ASU Biodesign InstituteTempe, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a randomized immunogenicity study in an enrolled cohort with active surveillance for influenza-like illness (ILI). During this study, participants will be randomly assigned to receive an approved cell culture-based influenza vaccine (Flucelvax®) versus a licensed comparator influenza vaccine (Flublok®). Blood samples from participants will be collected for measurement of biomarkers of immune response at baseline (visit 1; day 1), post-vaccination (visit 2; day 29), and post-season (visit 3; day 181). Participants will be asked if they wish to also provide saliva specimens at baseline (visit 1; day 1), post-vaccination (visit 2; day 29), and post-season (visit 3; day 181). Serum and peripheral blood mononuclear cells (PBMC) and plasma samples will be isolated from whole blood and tested for biomarkers of vaccine immunogenicity, and duration of antibody responses.

A teljes eredeti leírásKevesebb

Participants will receive electronic surveys via email or text message weekly asking about changes in health status and new ILI symptoms; those reporting illness may be asked to provide a respiratory swab for laboratory testing for influenza and other respiratory viruses and up to 2 additional blood draws (acute [<10 days after symptom onset] and convalescent [28 days after acute visit if lab-confirmed positive for influenza]).

A vizsgálat 2 csoportja

  • Flucelvax® (ccIIV3)A vizsgált kezelés

    Participants will receive Flucelvax® (ccIIV3) at Visit 1.

  • Flublok® (RIV3)A vizsgált kezelés

    Participants will receive Flublok® (RIV3) at Visit 1.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Measuring Immunity Against Circulating Influenza Viruses: Randomized Immunogenicity Study Among US Adults Aged 18-64 Years Comparing Two Approved Influenza Vaccines
Publikációk
A regiszteradat frissítve
2026. július 28.